ALX Oncology Holdings Inc. (ALXO)

Market Cap	204.74M
Revenue (ttm)	n/a
Net Income (ttm)	-123.48M
Shares Out	42.57M
EPS (ttm)	-3.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,073,953
Open	4.73
Previous Close	4.61
Day's Range	4.62 - 5.07
52-Week Range	4.52 - 19.85
Beta	1.76
Analysts	Buy
Price Target	34.10 (+608.94%)
Earnings Date	May 8, 2023

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 17, 2020
• Employees: 55
• Stock Exchange: NASDAQ
• Ticker Symbol: ALXO

Analyst Forecast

According to 14 analysts, the average rating for ALXO stock is "Buy." The 12-month stock price forecast is $34.1, which is an increase of 608.94% from the latest price.

Price Target

$34.1

(608.94% upside)

Analyst Consensus: Buy